A new Inserm Transfert Technology Offers experience coming soon in April !

BIO13024-T1

M-CSF for preventing or treating myeloid cytopenia and related complications following hematopoetic stem cell transplantation

The invention relates to a method for preventing or treating myeloid cytopenia and related complications such as infections in patients undergoing hematopoietic stem cell transplantation (HSCT). The approach is based on the priming of the hematopoietic stem cell graft with […]

BIO10412-T1

Recombinant flagellin for preventing and treating respiratoryinfections / COPD-AE

The present invention relates to the use of an optimized truncated flagellin (TLR5 agonist devoided of toxic effect) for preventing or treating respiratory tract infection. Both preventive and currative effects in the absence of any antibiotic have been demonstrated in […]

BIO15066-T1

Ex-vivo active immunotherapy against infectious diseases and tumoral antigens for mimicking natural production by B cells of immunoglobulin

The present invention concerns lentiviral vectors enabling the expression of membrane-anchored and secreted antibodies by B cells. This invention results from the development of a new method for adoptive transfer of B-cells transduced with a lentiviral vector (LV) conditionally expressing […]

BIO14444-T1

ANTIBODIES SPECIFIC TO GLYCOPROTEIN (GP) OF EBOLAVIRUS AND USES FOR THE TREATMENT AND DIAGNOSIS OF EBOLA VIRUS INFECTION

The present invention relates to antibodies or fragments thereof that specifically bind to glycoprotein (GP) of Ebola virus, and to their use for treating and diagnosing Ebola virus disease.

BIO13400-T1

Novel target candidate for the prevention and treatment of respiratory infections / COPD-AE

The present invention relates to methods and pharmaceutical compositions for the prevention and treatment of respiratory bacterial infections and more particularly of superinfection and acute exacerbation of chronic obstructive pulmonary disease with a therapeutically effective amount of an antagonist of […]

CHIM14143-T1

G quadruplex ligands to treat infectious diseases

The present inventions relate to – metallated porphyrin derivatives as ligands of G quadruplex and their use as anti-viral agents. Porphyrin derivatives candidates inhibits HIV replication with IC 50 around 100 nM in vitro. More specifically, this application is related […]

BIO17369-T1

Histone chaperone HIRA inhibitor for treating Hepatitis B Virus infection

The present invention concerns an inhibitor for use for preventing and/or treating an infection with hepatitis B virus (HBV) and an in vitro screening method for the identification of a candidate compound suitable for preventing and/or treating an infection with […]

BIO16215-T1

Mutated strain for the development of attenuated vaccine against Zika virus

The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation […]

BIO16236-T1

Mutated strain for the development of attenuated vaccine against Zika virus

The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were […]

BIO12303-T1

Prophylactic HIV vaccine

The invention relates to mAb based chimeric proteins allowing direct in-vivo targeting of antigens to the dendritic cells. GMP manufacturing of a prophylactic vaccine against HIV is ongoing and first in man is expected to start end of 2018.

12 Last patents posted


The 10 Last viewed

You haven't seen any form yet.